Treatment of autonomous ovarian follicular cyst with long-term anastrozole therapy

Ozlem Engiz, Özlem Engiz, Merih Berberoglu, Merih Berberoğlu, Zeynep Şıklar, Zeynep Siklar, Pelin Bilir, Gonul Ocal, Gönül Öçal
The Indian Journal of Pediatrics · 2009 · vol. 76(9) , pp. 950–951 · doi:10.1007/s12098-009-0190-2 · PMID:19904510 · W2092666357
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-01 ⓘ

Anastrozole successfully treated a recurrent autonomous ovarian follicular cyst in a girl with peripheral precocious puberty without adverse reactions, demonstrating its safety and tolerability for suppressing estrogen action.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Functional follicular ovarian cysts are frequently reported in girls with peripheral precocious puberty (PP). These cysts are usually self-limiting and resolve spontaneously. Several drugs like antiestrogens (tamoxifen) and new aromatase inhibitors are seldom used for treatment. Here we report a girl with peripheral PP who presented with unilateral enlargement of the ovary and a recurrent autonomous ovarian cyst. No skin pigmentation or bone anomaly was noted. The patient was successfully treated with anastrozole, a highly selective aromatase inhibitor. No adverse reaction was noted. Anastrozole is a safe and tolerable drug especially used to suppress estrogen action.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (11)

Source provenance

crossref
last seen: 2026-05-17T01:00:14.166772+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
unpaywall
last seen: 2026-09-27T06:17:51.937953+00:00
License: CC0 · commercial use OK